LEEM's five-point plan for France's CT future

1 December 2008

France's research-based pharmaceutical association, the LEEM, has published its biennial investigation into the state of clinical research for industrial purposes. The 2008 edition of the report found that France's position in global terms is broadly maintained, although there is a relative decline versus the rest of Europe. The study was conducted with 19 international innovative drugmakers, including eight of the world's top 10. In order to maintain national competitiveness, the LEEM proposes a five-point plan for the future.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight